A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, PHASE 3, PARALLEL-GROUP DESIGN STUDY EVALUATING THE EFFICACY AND SAFETY OF EFGARTIGIMOD IV IN ADULT PARTICIPANTS WITH ACETYLCHOLINE RECEPTOR BINDING ANTIBODY SERONEGATIVE GENERALIZED MYASTHENIA GRAVIS

Registry ID

ARGX-113-2308

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

ARGENX BV

Start date

2025-02-17

Last update

2024-06-28

Conditions

• GENERALIZED MYASTHENIA GRAVIS (MG)."

Related clinical trials

• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF DESCARTES-08 IN PATIENTS WITH ACETYLCHOLINE RECEPTOR ANTIBODY-POSITIVE GENERALIZED MYASTHENIA GRAVIS
• AN OPEN-LABEL, UNCONTROLLED STUDY TO EVALUATE THE PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY AND ACTIVITY OF EFGARTIGIMOD PH20 SC IN PARTICIPANTS FROM 2 TO LESS THAN 18 YEARS OF AGE WITH GENERALIZED MYASTHENIA GRAVIS
• A LONG-TERM, SINGLE-ARM, OPEN-LABEL, MULTICENTER, FOLLOW-ON TRIAL OF ARGX- 113-2006 TO EVALUATE SAFETY OF EFGARTIGIMOD ADMINISTERED INTRAVENOUSLY IN CHILDREN WITH GENERALIZED MYASTHENIA GRAVIS
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ALXN1720 IN ADULTS WITH GENERALIZED MYASTHENIA GRAVIS
• A PHASE 3, MULTI-CENTER, RANDOMIZED, QUADRUPLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF BATOCLIMAB AS INDUCTION AND MAINTENANCE THERAPY IN ADULT PARTICIPANTS WITH GENERALIZED MYASTHENIA GRAVIS (GMG)
• OPEN-LABEL UNCONTROLLED TRIAL TO EVALUATE PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY, AND ACTIVITY OF EFGARTIGIMOD IN CHILDREN FROM 2 TO LESS THAN 18 YEARS OF AGE WITH GENERALIZED MYASTHENIA GRAVIS

View on source registry